Close

Zafgen (ZFGN) Reports Positive Topline Phase 1 Data for ZGN-1061

May 4, 2017 4:18 PM EDT Send to a Friend
Zafgen, Inc. (Nasdaq: ZFGN) today announced positive topline data from its Phase 1 clinical trial of ZGN-1061, the Company’s second ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login